BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

NCT03502577 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped Closed per SRC Low Accrual Policy

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

BIOLOGICAL: BCMA-specific CAR-expressing T Lymphocytes
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Gamma-Secretase Inhibitor LY3039478
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacokinetic Study

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]